Cargando…

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

Immunotherapy (eg interferon α) in combination with tyrosine kinase inhibitors is currently in clinical trials for treatment of chronic myeloid leukemia (CML). Cancer patients commonly have problems with so called immune escape mechanisms that may hamper immunotherapy. Hence, to study the function o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christiansson, Lisa, Söderlund, Stina, Svensson, Emma, Mustjoki, Satu, Bengtsson, Mats, Simonsson, Bengt, Olsson-Strömberg, Ulla, Loskog, Angelica S. I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561335/ https://www.ncbi.nlm.nih.gov/pubmed/23383287 http://dx.doi.org/10.1371/journal.pone.0055818

Ejemplares similares

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
por: Pfirrmann, Markus, et al.
Publicado: (2020)

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
por: Hjorth-Hansen, Henrik, et al.
Publicado: (2015)

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors
por: Karlsson, Hannah, et al.
Publicado: (2015)

Immune control in chronic myeloid leukemia
por: Ilander, Mette, et al.
Publicado: (2017)

Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients
por: Zaidi, Uzma, et al.
Publicado: (2019)

The Sokal Hoax: the sham that shook the Academy
por: Lingua Franca. USA
Publicado: (2000)

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
por: Huuhtanen, Jani, et al.
Publicado: (2022)

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
por: El Missiry, Mohamed, et al.
Publicado: (2017)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
por: Chhikara, Sunita, et al.
Publicado: (2018)

Cophenetic metrics for phylogenetic trees, after Sokal and Rohlf
por: Cardona, Gabriel, et al.
Publicado: (2013)

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
por: Mosakhani, Neda, et al.
Publicado: (2013)

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
por: Dolinska, Monika, et al.
Publicado: (2023)

Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy
por: Xia, Leiming, et al.
Publicado: (2015)

IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia
por: Ilander, Mette, et al.
Publicado: (2014)

Programmed Cell Death of Embryonic Motoneurons Triggered through the FAS Death Receptor
por: Raoul, Cédric, et al.
Publicado: (1999)

Senescent cells re‐engineered to express soluble programmed death receptor‐1 for inhibiting programmed death receptor‐1/programmed death ligand‐1 as a vaccination approach against breast cancer
por: Chen, Zehong, et al.
Publicado: (2018)

The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor
por: Al Attar, Layth, et al.
Publicado: (2018)

Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond
por: Zhang, Junxia, et al.
Publicado: (2018)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
por: Maughan, Benjamin L., et al.
Publicado: (2017)

Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia
por: Löf, Liza, et al.
Publicado: (2017)

Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era—experience from a tertiary oncology centre in Southern India
por: Kuntegowdanahalli, Lakshmaiah Chinnagiriyappa, et al.
Publicado: (2016)

Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
por: Zhang, Xiao-Shuai, et al.
Publicado: (2021)

The Clinical Significance of Programmed Death-1, Regulatory T Cells and Myeloid Derived Suppressor Cells in Patients with Nontuberculous Mycobacteria-Lung Disease
por: Shu, Chin-Chung, et al.
Publicado: (2019)

Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus
por: Park, Min-Jung, et al.
Publicado: (2021)

Regulatory T Cells and Human Myeloid Dendritic Cells Promote Tolerance via Programmed Death Ligand-1
por: Amarnath, Shoba, et al.
Publicado: (2010)

Engagement of SIRPα Inhibits Growth and Induces Programmed Cell Death in Acute Myeloid Leukemia Cells
por: Irandoust, Mahban, et al.
Publicado: (2013)

The Influence of Programmed Cell Death in Myeloid Cells on Host Resilience to Infection with Legionella pneumophila or Streptococcus pyogenes
por: Gamradt, Pia, et al.
Publicado: (2016)

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
por: Wang, Shiqiang, et al.
Publicado: (2020)

Decreased programmed cell death ligand 2-positive monocytic myeloid-derived suppressor cells and programmed cell death protein 1-positive T-regulatory cells in patients with type 2 diabetes: implications for immunopathogenesis
por: Liu, Zhaoxiang, et al.
Publicado: (2023)

Structure and Interactions of the Human Programmed Cell Death 1 Receptor
por: Cheng, Xiaoxiao, et al.
Publicado: (2013)

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
por: Eriksson, E, et al.
Publicado: (2017)

Correction: The Influence of Programmed Cell Death in Myeloid Cells on Host Resilience to Infection with Legionella pneumophila or Streptococcus pyogenes
por: Gamradt, Pia, et al.
Publicado: (2017)

Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal
por: Fife, Brian T., et al.
Publicado: (2009)

Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis
por: Greisen, Stinne R., et al.
Publicado: (2017)

Seed Oil of Brucea javanica Induces Apoptotic Death of Acute Myeloid Leukemia Cells via Both the Death Receptors and the Mitochondrial-Related Pathways
por: Zhang, Hong, et al.
Publicado: (2011)

Vitamin D increases programmed death receptor-1 expression in Crohn’s disease
por: Bendix, Mia, et al.
Publicado: (2017)

Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody
por: Zhang, Lin, et al.
Publicado: (2022)

Programmed cell death
Publicado: (1994)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6mevra9nmtb0vqq8jgn4pftk4l